On September 1, 2026, AIM-listed Futura Medical (AIM:FUM, OTC:FAMDF) published first-half results that read like two different companies stapled together: a sexual-health pipeline hitting milestone after milestone, and a balance sheet with roughly a month of runway. The maker of Eroxon — the over-the-counter topical gel for erectile dysfunction, the first of its kind cleared for OTC sale in the U.S. and EU — reported revenue of £1.62 million for the six months to June 30, up from £1 million a year earlier, but £1.4 million of that came from a legal settlement with former partner Haleon rather than from selling gel.

Why It Matters

Eroxon is the closest thing the ED category has to a true consumer product — no prescription, no telehealth intake, no pill, just a gel you buy at a counter. That makes Futura a bellwether for whether sexual health can be sold like skincare rather than like medicine. The answer so far is uncomfortable: regulatory clearance and clinical data were never the hard part. Distribution and marketing spend were. Losing Haleon meant losing the retail muscle that gets a first-in-class product onto endcaps, and no amount of positive home-user data substitutes for that. For the broader sector, the story is a caution about partner concentration. A single consumer-health partner can be the entire go-to-market, which means a partnership unwinding is an existential event rather than a setback. Anyone underwriting a sexual-wellness company whose model rests on one big-box or big-pharma relationship should read Futura's half-year as a stress test. There's also a live catalyst worth watching. If FDA clearance for Eroxon Intense lands in Q4 as guided, Futura would hold a strengthened U.S. asset — but on current guidance the cash runs out in October, before that clearance arrives. The next few weeks will determine whether the company reaches its own milestone as an independent business or as somebody else's acquisition. WSD4000, meanwhile, is the quieter prize: a credible topical for female arousal remains one of the least-served segments in sexual health, and Futura is shopping it while it is at its weakest negotiating position.

The headline commercial move is a swap at the top of the U.S. funnel. Effective September 1, Futura appointed Market Performance Group as its new U.S. commercial partner for Eroxon, replacing Haleon after a two-month transition. Haleon — the consumer-health giant spun out of GSK — had been the brand's route into American pharmacy shelves; Market Performance Group is a brand-services and retail-execution firm, a materially different animal. Futura framed it as "a clearer route to rebuilding momentum in one of the world's largest erectile dysfunction markets." The company also said it is in advanced talks with new partners in China, Korea, Taiwan and Turkey, and has consolidated Eroxon manufacturing into a single global supplier.

The pipeline news is genuinely good. Eroxon Intense, a faster- and stronger-acting reformulation, cleared a home user test of 223 men aged 18–59 with what Futura called high efficacy, and has received EU market clearance. The company is targeting FDA clearance for Intense in the fourth quarter, with production expected to begin in early 2027. Separately, WSD4000 — Futura's gel aimed at female sexual arousal, the rarer half of the topical sexual-health market — produced a home user test in which 80% of women reported an improved overall sexual experience. Futura says it has opened early-stage partner discussions for WSD4000 across the U.S., Asia-Pacific, Europe and Latin America.

Then there is the arithmetic. Operating loss narrowed sharply to £1.2 million from £6.72 million (the prior-year figure included £4.05 million of exceptional costs), and administrative expenses fell after cost cuts. But cash stood at £1.06 million as of July 31, down from £1.24 million at the end of June, and the company stated plainly that existing resources fund operations only to approximately October without additional funding. The board says it is "progressing funding initiatives and wider strategic options" — corporate-speak that covers everything from a placing to a sale. Chief executive Alex Duggan characterised the half as "a period of significant strategic progress, strengthening the foundations of the business."

Sources

Update — 2026-09-02

Initial entry — story first created.